Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any immunodeficiency-centromeric instability-facial anomalies syndrome in which the cause of the disease is a mutation in the CDCA7 gene.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Global developmental delay, Depressed nasal bridge, Intellectual disability |
Head and neck | 2 | Microcephaly, Flat face |
Ears | 2 | Recurrent otitis media, Conductive hearing impairment |
Eyes | 1 | Strabismus |
Blood and immune system | 1 | Recurrent infections |
Growth and development | 1 | Intrauterine growth retardation |
CDCA7 encodes cell division cycle associated 7 (371 aa). Participates in MYC-mediated cell transformation and apoptosis; induces anchorage-independent growth and clonogenicity in lymphoblastoid cells. Highest expression in Cells EBV-transformed lymphocytes (54.1 TPM) and Small Intestine Terminal Ileum (20.8 TPM).
Immunodeficiency-centromeric instability-facial anomalies syndrome 3 has limited evidence linking it to mutations in the CDCA7 gene on chromosome 2.
CDCA7 is classified as a druggable target with score 0.0.
Genetic testing for CDCA7 is available. Testing is considered research-grade for diagnosis.
Phenotype severity distribution: 1 always present feature, 1 very common feature, 2 common features.
No clinical trials have been registered for immunodeficiency-centromeric instability-facial anomalies syndrome 3.
13 publications have been identified in PubMed for immunodeficiency-centromeric instability-facial anomalies syndrome 3. Research spans Basic Science / Preclinical (54%), Case Report / Case Series (23%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 7 | 54% |
Patient case studies | 3 | 23% |
Research summaries | 2 | 15% |
Clinical study results | 1 | 8% |
Givol O (2026). [PMID: 41359419](https://pubmed.ncbi.nlm.nih.gov/41359419/). *Hum Mol Genet*. [Case Report / Case Series]
Gao J (2026). [PMID: 41859080](https://pubmed.ncbi.nlm.nih.gov/41859080/). *Front Immunol*. [Case Report / Case Series]
Chen F (2026). [PMID: 42234582](https://pubmed.ncbi.nlm.nih.gov/42234582/). *Nucleic Acids Res*. [Basic Science / Preclinical]
Wang S (2025). [PMID: 41370347](https://pubmed.ncbi.nlm.nih.gov/41370347/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Unoki M (2025). [PMID: 40500184](https://pubmed.ncbi.nlm.nih.gov/40500184/). *Genes Genet Syst*. [Review / Meta-Analysis]
Roark CM (2025). [PMID: 40103177](https://pubmed.ncbi.nlm.nih.gov/40103177/). *Clin Exp Immunol*. [Case Report / Case Series]
Grillo G (2025). [PMID: 39562305](https://pubmed.ncbi.nlm.nih.gov/39562305/). *Hum Mol Genet*. [Basic Science / Preclinical]
Shinkai A (2024). [PMID: 39142653](https://pubmed.ncbi.nlm.nih.gov/39142653/). *Nucleic Acids Res*. [Basic Science / Preclinical]
Lullo V (2024). [PMID: 39040103](https://pubmed.ncbi.nlm.nih.gov/39040103/). *Front Immunol*. [Basic Science / Preclinical]
Cho CC (2024). [PMID: 39290110](https://pubmed.ncbi.nlm.nih.gov/39290110/). *Protein Sci*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:51 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center